X4 Pharmaceuticals highlights 2024 as transformative with XOLREMDI's U.S. launch, international expansion, & Phase 3 trial progress.
Voxel51, the leading solution for building visual AI applications, today unveiled three powerful built-in workflows to streamline data curation and model analysis, enabling enterprise teams to develop ...
The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...
The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...
Growth at a reasonable price, or GARP, is an excellent strategy to earn quick investment profits. The GARP approach helps identify stocks priced below the market or any suitable target determined by a ...
But if we can’t ban pharmaceutical ads, we can at least rein them in. Policymakers can play an integral role in addressing the manipulative advertising practices rampant in the industry, while still ...
Brand.com’s are connecting HCPs to information, with fewer hoops to jump through, courtesy of new digital tools promising to ...
Takeda Pharmaceutical has a robust drug discovery pipeline to meet future clinical demand. Check out the upside and downside ...
March 13, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ ... and comprehensive safety and efficacy data set that will become a central component of our regulatory approval submission. As ...
Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to co-develop a weight-loss treatment as the companies double down on ...
Samuel S Chowdhury, chairman of Square Pharmaceuticals, yesterday expressed his willingness to purchase 15 lakh shares of the company, valued at over Tk 32 crore at the current market price.